Cagrilintide Reconstitution Calculator

No. Cagrilintide is an investigational long-acting amylin analogue (dual amylin/calcitonin receptor agonist), and its fixed-dose combination with semaglutide (CagriSema) is described in the literature as investigational. Phase 3 programmes have reported complete data, REDEFINE 1/5 in obesity and REIMAGINE 1–3 in type 2 diabetes, but no regulatory approval is recorded in the evidence base. Products sold through research-peptide vendors are not approved pharmaceuticals (community protocol).

Subcutaneous only. Every randomized trial administered cagrilintide as a once-weekly subcutaneous injection; no oral formulation appears in the development pipeline. At steady state, CagriSema (the fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) reduces ad libitum energy intake by roughly 63% without measurably delaying gastric emptying in humans (RCT); no comparable energy-intake data exist for cagrilintide monotherapy, and cagrilintide alone is expected to slow gastric emptying. There is no comparative oral route to choose between.

Yes, no dose adjustment appears warranted. Single-dose studies found similar total exposure (AUC) across mild, moderate, and severe renal impairment (AUC ratios 1.18–1.23 vs normal) and hepatic impairment (0.99–1.11 vs normal), with no consistent exposure pattern or added safety findings (RCT). No human pregnancy or lactation data exist; weight-loss peptides are generally avoided in pregnancy (practitioner consensus).

Monotherapy at 26 weeks produced dose-dependent weight loss of 6–10.8% vs 9.0% for liraglutide 3 mg/day and 3% for placebo (RCT); pooled analyses show monotherapy weight loss comparable to semaglutide/liraglutide but with significantly lower vomiting. CagriSema beats semaglutide: −7.58 kg greater loss (95% CI −10.30 to −4.86), and −18.4% vs −11.9% in REDEFINE 5 (RCT). Versus tirzepatide 15 mg, network meta-analyses place CagriSema nearly identical on mean loss (−17.84% vs −17.97%) but ahead at the ≥20% threshold (RR 27.82 vs 23.70); one-year estimates are −14.8% vs −14.9%. Gastrointestinal adverse events run higher with CagriSema than either monotherapy (58% vs 32–33% in phase 2).

Hypoglycemia is not a prominent feature of CagriSema or cagrilintide used alone: phase 2 data reported no level 2 or 3 hypoglycemia with CagriSema, semaglutide, or cagrilintide, though level 1 events (blood glucose 55–69 mg/dL) were more frequent with CagriSema (7%) and cagrilintide (6%) than with semaglutide (0%) (RCT). When added to basal insulin in the phase 3 REIMAGINE 3 trial, no severe hypoglycemia was reported and CagriSema did not increase hypoglycemia risk versus placebo (RCT). With sulfonylureas or insulin, standard glucose monitoring and possible downward dose adjustment of the background agent apply (practitioner consensus).

CagriSema lowers blood pressure. In the 68-week REDEFINE 1 trial, systolic blood pressure fell 10.9 mmHg with CagriSema 2.4 mg/2.4 mg versus 2.8 mmHg with placebo, and diastolic by 5.4 versus 1.7 mmHg; 63.0% of CagriSema recipients reached blood-pressure targets versus 32.0% with placebo (RCT). People taking antihypertensive medication should anticipate monitoring and possible dose reductions as blood pressure and weight fall (practitioner consensus).

Trial maintenance dose is 2.4 mg once weekly, reached by stepwise escalation over ~16 weeks from a low starting dose; an alternative clinical-pharmacology schedule escalates every 4 weeks to 2.4 mg. Supratherapeutic dosing to 4.5 mg was tested and tolerated in a QT study. Community practice mirrors this: start at 0.25–0.5 mg weekly and step up every 4 weeks as tolerated toward 2.4 mg (community protocol).

Gastrointestinal events dominate and are mostly mild–moderate during dose escalation (RCT): nausea occurred in 55% of CagriSema recipients in REDEFINE 1, with discontinuation rates of only 6–8.4%. Network meta-analyses show fatigue increased with CagriSema (RR 3.2; ~92 more per 1000/year) but serious adverse events comparable to placebo. No clinically relevant QTc prolongation was seen at 4.5 mg.

Published phase 3 trials ran 40–68 weeks (68 weeks is the longest), with earlier phase 2 trials as short as 20–32 weeks. Obesity is relapsing and weight regain upon cessation is characteristic of incretin-based therapies; treatment is framed as chronic with no established stop rule (practitioner consensus). Long-term safety beyond 68 weeks is untested.

No published storage conditions exist for the investigational product. Standard guidance for peptide injectables is refrigeration at 2–8°C, with short room-temperature excursions acceptable if kept cool and dark; avoid freezing (community protocol). Multiweek pens, if obtained, should stay refrigerated between doses (practitioner consensus).